Roche licensed exclusive global rights to Simcere Zaiming’s SIM0660, a CD79axCD19xCD3 trispecific T-cell engager intended for B-cell malignancies and autoimmune diseases. Simcere will receive $75 million upfront, up to $1.455 billion in development, regulatory…
A full peer-reviewed analysis of Roche and Genentech’s cevostamab phase 1 program establishes FcRH5 as a clinically active multiple-myeloma target. At the 160 mg recommended phase 2 dose, fixed-duration cevostamab produced a 44.3% objective…
Nurix and Roche closed their global bexobrutideg collaboration after the Hart-Scott-Rodino waiting period expired. Closing converts a previously announced agreement into an operative partnership and triggers a $700 million upfront payment, with up to…
Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave Life Sciences and its allele-selective antisense oligonucleotide candidate, WVE-003.The key distinction is biological selectivity. Tominersen was designed to lower total…
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
